Literature DB >> 6090712

Identification of multiple Epstein-Barr virus-induced nuclear antigens with sera from patients with rheumatoid arthritis.

T B Sculley, P J Walker, D J Moss, J H Pope.   

Abstract

By means of the protein immunoblot technique, the Epstein-Barr virus (EBV) nuclear antigen (EBNA) could be identified in a variety of EBV-transformed cell lines with anti-EBNA-positive sera from normal donors. The molecular weight of EBNA expressed in each of the cell lines varied between 70,000 and 75,000 and was dependent upon the strain of infecting virus. In contrast, 15 of 21 sera from patients with rheumatoid arthritis identified antigens in addition to EBNA. The most prominent of these antigens had molecular weights of 110,000 to 115,000 and 92,000. All of the EBV genome-positive cell lines except for QIMR-GOR and cell lines containing the P3HR-1 virus expressed these antigens. The antigens were not present in the EBV genome-negative Ramos and BJAB cell lines, nor were they identified with EBV seronegative sera, indicating that they were EBV related. There was no direct correlation between the presence of antibodies in sera to EBNA, viral capsid antigen or early antigen, and reaction with the 92,000-molecular-weight antigen in immunoblots, indicating that this antigen was distinct from previously described EBV-related antigens.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6090712      PMCID: PMC254493     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genome.

Authors:  G Klein; L Dombos
Journal:  Int J Cancer       Date:  1973-03-15       Impact factor: 7.396

2.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

3.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

4.  Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji).

Authors:  M A Epstein; B G Achong; Y M Barr; B Zajac; G Henle; W Henle
Journal:  J Natl Cancer Inst       Date:  1966-10       Impact factor: 13.506

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Identification of the filtrable leukocyte-transforming factor of QIMR-WIL cells as herpes-like virus.

Authors:  J H Pope; M K Horne; W Scott
Journal:  Int J Cancer       Date:  1969-05-15       Impact factor: 7.396

7.  Establishment of cell lines from Australian leukaemic patients: presence of a herpes-like virus.

Authors:  J H Pope
Journal:  Aust J Exp Biol Med Sci       Date:  1968-10

8.  Burkitt lymphoma in New Guinea: establishment of a line of lymphoblasts in vitro and description of their fine structure.

Authors:  J H Pope; B G Achong; M A Epstein; J Biddulph
Journal:  J Natl Cancer Inst       Date:  1967-11       Impact factor: 13.506

9.  Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.

Authors:  Y Hinuma; M Konn; J Yamaguchi; D J Wudarski; J R Blakeslee; J T Grace
Journal:  J Virol       Date:  1967-10       Impact factor: 5.103

10.  Comparison of the yield of infectious virus from clones of human and simian lymphoblastoid lines transformed by Epstein-Barr virus.

Authors:  G Miller; M Lipman
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

View more
  18 in total

1.  Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjögren's syndrome patients with pulmonary involvements.

Authors:  M Yamazaki; R Kitamura; S Kusano; H Eda; S Sato; M Okawa-Takatsuji; S Aotsuka; K Yanagi
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

2.  Induction of Epstein-Barr virus nuclear antigens.

Authors:  D J Moss; T B Sculley; J H Pope
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

3.  Definitive identification of a member of the Epstein-Barr virus nuclear protein 3 family.

Authors:  K Hennessy; F Wang; E W Bushman; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

Review 4.  Molecular virology of Epstein-Barr virus.

Authors:  G W Bornkamm; W Hammerschmidt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

5.  Reaction of antibodies to rheumatoid arthritis nuclear antigen with a synthetic peptide corresponding to part of Epstein-Barr nuclear antigen 1.

Authors:  P J Venables; T Pawlowski; P A Mumford; C Brown; D H Crawford; R N Maini
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

Review 6.  Epstein-Barr virus infection and autoimmunity in rheumatoid arthritis.

Authors:  P Venables
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

Review 7.  The Epstein-Barr virus in autoimmunity.

Authors:  J H Vaughan
Journal:  Springer Semin Immunopathol       Date:  1995

8.  Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.

Authors:  A Leen; P Meij; I Redchenko; J Middeldorp; E Bloemena; A Rickinson; N Blake
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

9.  Rheumatoid factors induce signaling from B cells, leading to Epstein-Barr virus and B-cell activation.

Authors:  Lixin Yang; Masayuki Hakoda; Kazuya Iwabuchi; Tsuyoshi Takeda; Takao Koike; Naoyuki Kamatani; Kenzo Takada
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells.

Authors:  B Kallin; J Dillner; I Ernberg; B Ehlin-Henriksson; A Rosén; W Henle; G Henle; G Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.